Ascendiant Capital Markets Issues Positive Forecast for PAVmed (NASDAQ:PAVM) Stock Price

PAVmed (NASDAQ:PAVM) had its price target lifted by stock analysts at Ascendiant Capital Markets from $56.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Weiss Ratings downgraded shares of PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $57.00.

PAVmed Trading Up 0.8%

NASDAQ PAVM opened at $5.32 on Thursday. The business’s fifty day moving average is $5.21 and its 200-day moving average is $7.34. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a market capitalization of $42.54 million, a price-to-earnings ratio of -0.33 and a beta of 0.54. PAVmed has a one year low of $3.85 and a one year high of $28.44.

Institutional Trading of PAVmed

Several hedge funds have recently made changes to their positions in PAVM. Two Seas Capital LP purchased a new position in shares of PAVmed during the 2nd quarter valued at $2,742,000. Geode Capital Management LLC increased its holdings in PAVmed by 74.8% in the 4th quarter. Geode Capital Management LLC now owns 168,832 shares of the company’s stock worth $40,000 after acquiring an additional 72,258 shares during the last quarter. Jane Street Group LLC increased its holdings in PAVmed by 392.9% in the 2nd quarter. Jane Street Group LLC now owns 52,676 shares of the company’s stock worth $32,000 after acquiring an additional 41,990 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in PAVmed in the 2nd quarter valued at about $102,000. 19.93% of the stock is currently owned by institutional investors.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.